






































































Cannabidiol and Tetrahydrocannabinol concentrations in commercially available CBD E-
liquids in Switzerland 
 
Abstract 
Cannabidiol (CBD) rich hemp and hemp products low in Δ9-tetrahydrocannabinol (THC) (less than 1 
%) are legally available in Switzerland. Besides herbs for smoking and oils, liquids (e-liquids) for 
smoking in electronic cigarettes (e-cigs) have recently appeared on the market. These e-liquids are 
available with different CBD concentrations and can be flavoured. The aim of the current study was to 
investigate 20 e-liquids legally available in Switzerland for their contents using Fourier-transform 
infrared spectroscopy (FTIR) as a preliminary step followed by gas-chromatography coupled to mass 
spectrometry to identify potential cannabinoids, natural plant compounds and flavours. Quantification 
of CBD, cannabidiol carboxylic acid (CBD-acid), cannabinol (CBN), Δ9-tetrahydrocannabinol (THC), 
and Δ9-tetrahydrocannabinol carboxylic acid A (THC-acid) was performed by a validated method with 
ultra-high-pressure-liquid chromatography coupled to a diode array detector (UHPLC-DAD). 
FTIR analysis could confirm that for all investigated samples the e-liquid matrix consisted of 1,2-
propanediol and glycerol. The qualitative GC-MS could identify ten phytocannabinoids including the 
quantified analytes, six natural plant compounds and five flavours.  
All analysed samples had a total THC content below 0.1059 % (by weight), hence meeting the legal 
requirements of both Switzerland (< 1%) and the European Union (< 0.2%). The total CBD content 
ranged from 0.182 to 3.346 % and differed in ten out of 20 samples from the CBD content presented 
by the manufacturer by more than 10 % relative CBD. Furthermore, two of the analysed samples 
contained only 0.348 % and 0.182 % total CBD despite being labelled as "CBD rich". Seven of the 20 
samples contained the correct CBD content (in the range of the labelled CBD content ± 10 %).  
In conclusion, a deviation in the determined total CBD content from the labelled CBD content could 
be observed for half of the analysed samples, meaning that consumers cannot rely on the 
manufacturers' information. It is remarkable, that currently no official regulations for providing correct 
information of CBD content or any external product control is available in Switzerland and in most 






In Switzerland the legal status of cannabis is regulated by the Federal Act on Narcotics and 
Psychotropic Substances (BetmG 812.121). Cannabis is considered illegal if the total 
tetrahydrocannabinol (THC), the main psychoactive component of marihuana, content exceeds 1 %. 
However, Cannabidiol (CBD) rich hemp with a total THC content below 1 % can be legally obtained 
as a tobacco substitute product, CBD rich oils or in so called e-liquids [1, 2], which are mainly 1,2-
propanediol (propylene glycol) and glycerol based (see Table 1).  
Cannabis sativa contains 489 naturally compounds of which roughly 90 are phytocannabinoids [3, 4]. 
These substances are terpenophenols, which are mostly responsible for the plants psychoactive effects 
[3]. The main psychoactive compound of cannabis is Δ9-tetrahydrocannabinol (Δ9-THC), producing 
euphoria, relaxation analgesic, anti-inflammatory, appetite stimulating and antiemetic effects [5]. Yet, 
chronic Δ9-THC consumption has been associated with severe side effects such as cognitive deficits, 
anxiety, paranoia, chronic psychosis and dependence [6-8]. CBD is a non-psychoactive isomer of Δ9-
THC and has anti-inflammatory, anticonvulsive, anxiolytic, analgesic, neuroprotective, anticancer and 
antioxidant effects [9].  
Since 2006, vaping with electronic cigarettes (e-cigarettes) has become popular as an alternative to 
smoking cigarettes [10]. Different generations of e-cigarettes are available such as atomizers, 
cartomizers or clearomizers. Clearomizers are the most common consisting of a disposable head 
containing the heating coil and wicks converting the electronic liquids (e-liquids) into an aerosol 
(vapour), and a clear tank containing the e-liquid [11]. E-liquids commonly consist of 1,2-propanediol 
and vegetable glycerol and can additionally contain nicotine or different flavours (see Table 1). In 
Switzerland, recently, e-liquids containing Δ9-THC or CBD have appeared on the market. 
Additionally, e-liquids containing synthetic cannabinoids have been reported to be found in Germany, 
Poland and in the USA [12-14].  
A reason for the popularity of vaping could be that earlier publications claimed that the produced vape 
contains fewer harmful chemicals compared to ordinary cigarettes or joints [15, 16]. However, recent 
studies have shown that e-liquid vapour induces oxidative stress, glutathione depletion and increased 
production of inflammatory cytokines in human airway epithelial cells in vitro and in lungs of mice in 
vivo [10, 17]. Staudt et al. demonstrated in their recent publication that short-time vaping (two 
exposures to vapour of 10 puffs with a 30 min break) is harmful to the lung even in the absence of 
nicotine [18].  
Recently, an increase of life-threating lung diseases (so called vaping-associated pulmonary illness 
(VAPI), over 1000 reported cases) and deaths (18 cases) has been reported in context with vaping of e-
liquids in Northern America [19, 20]. The Centres for Disease Control and Prevention (CDC) suspects 
Δ9-THC-containing and Δ9-THC- and nicotine-containing products to be responsible for these adverse 
effects but is still investigating [19]. Lately, the recreational use of marihuana has become legal in 
eleven US states and another 15 US states have decriminalized its consumption [21]. In Switzerland 
two cases of patients with lung diseases in relation with e-cigarettes have been reported [22].  
The aims of this study were to first investigate the composition of 20 different CBD rich e-liquids 
from Swiss headshops and a Swiss online retailer using Fourier-transform infrared spectroscopy 
(FTIR) and gas-chromatography mass spectrometry (GC-MS) to identify potential adulterations with 
synthetic cannabinoids, and second, to quantify the e-liquids' total Δ9-THC and CBD concentrations 
with a previously published validated method with ultra-high pressure-liquid chromatography coupled 





Table 1: List of investigated E-liquids.  
Sample 
number 





1 Cannabis Botanical 
Dreams Mix 
Merlins Garden Switzerland Werners head Shop 
Limmatquai 74 8001 
Zurich 
14.09.2019 not specified Flavourless not specified 
2 Original Hemp Marry Jane Mary Jane GmbH 





14.09.2019 100 mg Flavourless not specified 
3 Original Hemp Marry Jane Mary Jane GmbH 





14.09.2019 300 mg Flavourless not specified 
4 Strawberry Wild Harmony London, UK Hanfpost Wonderland 
Trading GmbH 
Kastelstrasse 89 2540 
Grenchen 
17.09.2019 100 mg Strawberry propylene glycol, vegetable 
glycerine, aroma, CBD (methyl 
cinnamate, furaneol) 
5 Kiwi Skunk Harmony London, UK Hanfpost Wonderland 
Trading GmbH 
Kastelstrasse 89 2540 
Grenchen, Switzerland 
17.09.2019 100 mg Kiwi propylene glycol, vegetable 
glycerine, aroma, CBD 
(Caryophyllen, D-limonen, 
linalool, β-pinen) 
6 Exodus Cheese Harmony London, UK Hanfpost Wonderland 
Trading GmbH 
Kastelstrasse 89 2540 
Grenchen, Switzerland 
17.09.2019 100 mg Cheese vegetable glycerine, propylene 
glycol, aroma, CBD 
(caryophyllen, D-limonen, 
linalool, α-pinen, β-pinen) 
7 Moroccan Mint Harmony London, UK Hanfpost Wonderland 
Trading GmbH 
Kastelstrasse 89 2540 
Grenchen, Switzerland 
17.09.2019 100 mg Mint vegetable glycerine, propylene 
glycol, aroma, CBD (carvone, 
D-limonen) 
8 New-York Diesel Harmony London, UK Hanfpost Wonderland 
Trading GmbH 
Kastelstrasse 89 2540 
Grenchen, Switzerland 
17.09.2019 100 mg Diesel vegetable glycerine, propylene 





9 Original Hemp Harmony London, UK Hanfpost Wonderland 
Trading GmbH 
Kastelstrasse 89 2540 
Grenchen, Switzerland 
17.09.2019 100 mg Flavourless vegetable glycerine, propylene 
glycol, aroma, CBD 
10 Cannabis Botanical 
Dreams- Zitrone 
Merlins Garden Switzerland Hanfpost Wonderland 
Trading GmbH 
Kastelstrasse 89 2540 
Grenchen, Switzerland 
17.09.2019 not specified Flavourless 60 % propylene glycol, 19 % 
herb extract, 17 % glycerine, 4 
% dest. Water, 1% lemon oil 
11 Cannabis Botanical 
Dreams-Orange 
Merlins Garden Switzerland Hanfpost Wonderland 
Trading GmbH 
Kastelstrasse 89 2540 
Grenchen, Switzerland 
17.09.2019 not specified Flavourless 60 % propylene glycol, 19 % 
herb extract, 17 % glycerin, 4 
% dest. Water, 1% orange oil 
12 Freedom Cannaliz® 
Terpenes+ 
Cannatract Labs des 




Kastelstrasse 89 2540 
Grenchen, Switzerland 
17.09.2019 300 mg not 
specified 
45.5 %propylene glycol USP, 
45.5 vegetable glycerine USP, 
6 % Organic hemp flower cold-
alcohol-extract, 3 % added 
terpenes (terpinolone, 
caryophyllene, myrcene, 
limonene), 0 % nicotin 
13 Dreams Cannaliz® 
Terpenes+ 
Cannatract Labs des 




Kastelstrasse 89 2540 
Grenchen, Switzerland 
17.09.2019 300 mg not 
specified 
45.5 % propylene glycol USP, 
45.5 vegetable glycerine USP, 
6 % Organic hemp flower cold-
alcohol-extract, 3 % added 
terpenes (myrcene, 
caryophyllene, α-pinene, β-
Pinene), 0 % Nikotin 
14 Mojito Cannaliz® 
Terpenes+ 
Cannatract Labs des 




Kastelstrasse 89 2540 
Grenchen, Switzerland 
17.09.2019 300 mg Mojito 45.5 % propylene glycol USP, 
45.5 vegetable glycerine USP, 
6 % Organic hemp flower cold-
alcohol-extract, 3 % added 
terpenes (linalol, 
caryophyllene, limonene, 
mentol ), 0 % nicotin 
15 Tangie Swiss E-
liquid/Pure 
Production 
Pure Produciton Ag 
CBD-Shop hanfhof.ch 




Kastelstrasse 89 2540 
Grenchen, Switzerland 
17.09.2019 1% not 
specified 
propylene glycol, vegetable 
glycerine, natural aroma tangie, 
vegetable pure CBD 1 % 
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16 Amnesia Swiss E-
liquid/Pure 
Production 
Pure Produciton Ag 
CBD-Shop hanfhof.ch 




Kastelstrasse 89 2540 
Grenchen, Switzerland 
17.09.2019 1% not 
specified 
propylene glycol, vegetable 
glycerine, natural aroma 
amnesia, vegetable pure CBD 1 
% 
17 Critical Swiss E-
liquid/Pure 
Production 
Pure Produciton Ag 
CBD-Shop hanfhof.ch 




Kastelstrasse 89 2540 
Grenchen, Switzerland 
17.09.2019 1% not 
specified 
propylene glycol, vegetable 
glycerine, natural aroma 
critical, vegetable pure CBD 1 
% 
18 Lemon Mary Jane Mary Jane GmbH 




8001 Zurich  
11.10.2019 1% Lemon propylene glycol, glycerine, 
CBD, aroma 
19 Strawberry Wild Mary Jane Mary Jane GmbH 




8001 Zurich  
11.10.2019 1% Strawberry glyercine E422, propylene 
glycol E1520, Cannabis Sativa 
L. ethanol extract 
20 Melon  Mary Jane Mary Jane GmbH 




8001 Zurich  
11.10.2019 1% Melon glyercine E422, propylene 
glycol E1520, Cannabis Sativa 






Chemicals and reagents 
Ultrapure water was produced in-house using the direct-Q purification system from Millipore (Zug, 
Switzerland). Acetonitrile (HPLC gradient grade, 99.9 %) was purchased from Acros Organics 
(Chemie Brunschwig, Basel, Switzerland), n-hexane (EMSURE®) from Merck (Darmstadt, 
Germany), methanol (absolute, HPLC grade) from Biosolve (Chemie Brunschwig, Basel, 
Switzerland), formic acid solution (puriss p.a., 50 % in water), 1,2-propanediol (> 99.5 %) and 
glycerol (> 99.5%) from Sigma-Aldrich (Buchs, Switzerland). The reference standards of THC, 
tetrahydrocannabinolic acid A (THC-acid), CBD, cannabidiolic acid (CBD-acid) and cannabinol 
(CBN) were obtained from Lipomed (Arlesheim, Switzerland).  
E-liquids 
Twenty different e-liquids from five different manufacturers were purchased from two different 
headshops in Zurich, Switzerland and from the internet (www.hanfpost.ch) (compare Table 1). 
According their label, they contain 100-300 mg (1-3 %) of CBD with the exception of sample 1, 10 
and 11 (Cannabis Botanical Dreams-Mix/ Zitrone/ Orange), which had no specification. Fourteen e-
liquids were produced in Switzerland and six in London, UK (manufacturer Harmony) according to 
their label. Six e-liquids were unflavoured (sample 1-3, 9-11) and 14 were flavoured (sample 4-8, 12- 
20).  
Sample preparation 
For the qualitative GC-MS analysis of the e-liquids, 200 µL e-liquid were transferred into a 
polypropylene vial and extracted with 1000 µL of a mixture of n-hexane/ ethyl acetate (7:3, v/v). 
Samples were shaken for five minutes followed by centrifugation for 10 min at 8 °C and 17,000 g. The 
supernatant was transferred into a new vial and an aliquot of 10 µL was diluted with 990 µL ethyl 
acetate. 
Sample preparation for the quantification of CBD, CBD-acid, CBN, THC and THC-acid using 
UHPLC-DAD was as follows: 150 mg of e-liquid were diluted with 10 mL of a mixture of methanol/ 
n-hexane (9:1, v/v). Aliquots were diluted 1:10 (v/v) and 1:20 (v/v) with the methanol/n-hexane 
mixture and transferred to another autosampler vial, respectively. To measure the low CBD-acid, 
CBN, THC and THC-acid concentrations, 150 mg e-liquid were diluted with 1 mL methanol/n-hexane 
mixture, shaken, ultrasonicated and directly transferred to an autosampler vial for analysis. Samples 
were analysed in duplicates.  
Qualitative analysis 
FTIR and GC-MS were used for qualitative analysis. Our laboratory has been accreditated according 
to ISO 17025:2018 in 2019 for Forensic Chemistry – including these two methods for qualitative 
analysis. The validation included determination of specificity and selectivity as well as sensitivity for a 
selection of drugs including synthetic cannabinoids. 
Qualitative analysis using Fourier-transform infrared spectroscopy  (FTIR) 
In order to identify the solvent of the tested e-liquids an FTIR spectrometer with a Universal‐
Attenuated‐Total‐ Reflectance  polarization accessory (FTIR‐UATR) and Spectrum v2.00 software  
(Perkin Elmer, Schwerzenbach, Switzerland) was used. Scan range was from 4000 cm−1 to 400 cm−1 
with a resolution of 4 cm−1. The liquid samples were directly analyzed without any pretreatment. For 
identification the following libraries were used: Drugs (Perkin Elmer, Massachusetts, USA), BAG 




Qualitative analysis using GC-MS with electron impact ionisation (EI) 
The e-liquids were qualitatively analysed using a 6890N gas chromatograph with a 7683B 
autosampler coupled to a 5973 inert mass spectrometer (Agilent, Basel, Switzerland). 
Chromatographic separation was performed on a 5 % phenyl methyl polysiloxane capillary column 
(30 m, 0.25 mm i.d., film thickness 0.25 µm; Perkin Elmer, Schwerzenbach, Switzerland). The total 
run time was 30.5 min and a temperature gradient was applied: 0-3 min: 80 °C, 3-7 min: 20 °C/min to 
150 °C, 7-22 min: 10 °C/min to 300 °C, held at 300 °C for 8.5 min. Helium gas was used as carrier gas 
with a flow rate of 1 mL/min. The injection volume was set to 1 µL (splitless) and the solvent delay 
was 3 min. EI mass spectra were aquired with a 70 eV ionisation energy. The mass spectrometric scan 
range was from m/z 25 to 700 with a scan time of 1 sec/scan in the time window of 3.1 to 30 min.  
Glycerol and 1,2-propanediol were confirmed by full-scan GC-MS analysis in EI-mode (same 
instrumentation) using a modified gradient: 0 – 2 min: 35 °C; 2 min – 3 min: 20°C/min to 55°C, 3 
min: 40°C/min to 310°C, hold time: 8 min, with split-injection (split ratio 1: 30) of a 1.5mg/mL 
solution of the e-liquid in methanol/hexane (99:1, v/v). Retention times and characteristic masses (1,2-
propanediol: 3.7 min; m/z 45, 43, 61; glycerol: 5.6 min; m/z 61, 43, 42).  
For compound identification the mass spectral libraries "Wiley Registry of Mass Spectral Data with 
NIST" and "SWGDRUG MS Library" Version 3.5.L (September 23, 2019) were used. 
The chromatograms and mass spectra were reproduced using GraphPad Prism 8.1.0. 
Quantitative analysis using UHPLC-DAD  
The quantification of CBD, CBD-acid, CBN, THC and THC-acid was carried out according to a 
previously published method [23] with an UltiMate 3000 UHPLC system (Dionex, Olten Switzerland) 
consisting of a HPG-3400RS binary pump, a WPS-3000TRS autosampler, a TCC-3000RS column 
compartment coupled to a DAD-3000RS detector with Chromeleon software Version 6.8 (Thermo 
Scientific, Rheinach, Switzerland). Chromatographic separation was performed with a Kinetex C8 
column, 2.6 mm, 100 Å, 100 µm x 2.1 mm (Phenomenex, Basel, Switzerland) with the mobile phase 
consisting of water with 0.1 % formic acid (A) and acetonitrile with 0.1 % formic acid (B) and a flow 
rate of 0.6 mL/min. The following gradient was applied: 0–2 min: 50% B; 2–9 min: 50 % to 65% B; 
9–10 min: 65% B; 10–10.1 min: 65 % to 50% B; 10.1–13 min: 50% B. The temperature of the 
autosampler and column compartment were set to 8 °C and 25 °C, respectively. The injection volume 
was 5 µL. The detection wavelength for quantification was 210 nm.  
A six-point calibration was prepared in methanol for THC, CBD and CBN (0.001, 0.005, 0.01, 0.02, 
0.05 and 0.1 mg/mL) and a seven-point calibration in methanol for CBD-acid and THC-acid (0.01, 
0.05, 0.1, 0.2, 0.3, 0.4 and 0.5 mg/mL), respectively as described previously [23]. To obtain the total 
concentrations of CBD and THC, respectively, the concentrations of CBD and CBD-acid (or THC and 
THC-acid) are added up by using molar concentrations and then the sum of molar concentrations is 
recalculated as total CBD (or as total THC) concentration in g/100 g (weight %), thus compensating 
for a theoretical loss of CO2. This total CBD-concentration (or total THC-concentration) is used for 
reporting the total CBD or total THC content in the e-liquids. The conversion factor of CBD-acid to 
CBD – as well as for THC-acid to THC - is 0.88 ( MWCBD / MWCBD-acid = 314.47 g mol-1 / 358.48 g 
mol-1). 
For the calibration curves the analyte concentration (x) was plotted against the peak area by linear 
least-squares regression using a 1/x2 weighted factor. When the correlation coefficient (R2) is greater 
than 0.99, and the back-calculated calibrator concentrations were within ± 15% of the target value, 
linearity was acceptable. In order to determine selectivity of the method, the peak purity as well as the 
resolution of the analyte peaks from neighbouring peaks were assessed. Furthermore, the limits of 
detection (LODs) were defined as the concentration with a signal-to-noise ratio (S/N) of at least 3 by 
evaluation of the chromatograms of methanolic solutions containing decreasing concentrations of 
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analytes. The lower limit of quantification (LLOQ) was defined as the lowest calibrator of the 
respective calibration curve (THC, CBD and CBN 0.001 mg/mL, CBD-acid and THC-acid 0.01 
mg/mL). In order to access precision two authentic samples and two samples consisting of spiked 
matrix in low and high concentration (0.4 % and 4%) were measured in sextuplets. Intra-assay 
precision was determined from six replicates in a single run. Spiked samples consisted of 1,2-
propanediol and glycerol (70:30, w/w) and were spiked with methanolic solutions containing CBD, 
THC, CBN, CBD-acid and THC-acid to obtain a final concentration of cannabinoids of 0.4 % (sample 
A) or 4 % (sample B), respectively. Authentic and spiked samples were worked up as described 
earlier. Precision was expressed as percent relative standard deviation (%RSD) and was expected to be 
± 20%RSD. Carry-over was assessed in six independent runs by injection of methanol/n-hexane (9:1, 
v/v) directly after the highest calibrators. Absence of carry-over was proven if the analyte peak in the 
solvent sample was lower than 20% of the LLOQ response. The chromatograms were reproduced 
using GraphPad Prism 8.1.0. 
Results and Discussion 
Twenty different CBD rich e-liquids from two different headshops and from the internet were 
qualitatively and quantitatively analysed using FTIR, GC-MS and UHPLC-DAD.  
Qualitative analysis 
Propylene glycol (1,2 propanediol) and glycerol (glycerine, propane-1,2,3-triol) were the best hits 
found by library search for the major solvents of the e-liquids by FTIR (Figure 1) and GC-MS (EI 
mode) (Figure 2) in all samples.  
 
Figure 1: FTIR spectra of sample 3 (red, upper spectra) and library matches of a) 1,2-propanediol 
(propylene glycol) b) and glycerol acquired in the range of 4000 cm-1 to 400 cm-1. Hits by library 




Figure 2: GC-MS (EI mode): a) representative total-ion chromatogram of e-liquid matrix of sample 13 
and the corresponding mass spectra of b) 1,2-propanediol and c) glycerol.  
In total ten different phytocannabinoids were identified by GC-MS, namely: CBD, CBN, Δ9-THC, Δ8-
THC, Cannabicitran, Cannabielsoic acid, Cannabicyclol, Cannabidivarin, Cannabigerol, and 
Cannabichromene (see Figure 3 and Table 2). In all 20 samples the presence of CBD was confirmed 
and in 18 samples (samples 1-9 and 12-20) Δ9-THC could be found. Cannabicitran and cannbielsoic 




Figure 3: Chemical structures with their molecular formulas of the five phytocannabinoids quantified 
by UHPLC and the five additionally phytocannabinoids, which have been identified by GC-MS. 
 
Figure 4: Mass spectra of three of the identified phytocannabinoids a) CBD, b) Δ9-THC, c) 




Table 2: Identified phytocannabinoids in the respective e-liquid using GC-MS. +: detected and identified by GC-MS; -: not detected 
Sample CBD CBN Δ9-THC Δ8-THC Cannabicitran Cannabielsoic acid Cannabicyclol Cannabidivarin Cannabigerol Cannabichromene 
1 + - + + + - - - - - 
2 + - + - + + - - - - 
3 + - + + + + + - - - 
4 + - + + + - - + - - 
5 + - + - + + - + - - 
6 + - + + + + - - - - 
7 + - + - + + - + - - 
8 + - + - - + + + - - 
9 + - + + + + - - - - 
10 + - - - - - - - - - 
11 + - - - - - - - - - 
12 + + + + + + + + + - 
13 + + + - + + - + + + 
14 + + + - + + - + + + 
15 + - + - + + - - - - 
16 + - + + + - + - - - 
17 + - + - + + - - - - 
18 + - + - - + - - - - 
19 + - + - + + - - - - 






Besides the ten phytocannabinoids further six natural plant compounds (squalene, α-caryophyllene, β-
caryophyllene, caryophyllene oxide, nerolidol) and five flavours (methyl cinnamate, α-damascone, 
monomethyl succinate, γ-decalacton, hedione and rasperry ketone) were identified by GC-MS 
(compare Figure 5 and Table 3).  
 
Figure 5: Chemical structures and their molecular formulas of additives and flavours in the 20 
analysed e-liquids identified by GC-MS.  
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Table 3: Flavouring agents and other compounds in the 20 analysed e-liquids identified by GC-MS. +: detected and identified; -: not detected 
 



















1 - - - - - - - - - - - - 
2 - - - - - - - - - - - - 
3 - - - - - - - - - - - - 
4 - - - - - - + + + + + + 
5 + + + + + + - - - - - - 
6 - + + + - + - - - - - - 
7 - - - - - - - - - - - - 
8 - + + + - + - - - - - - 
9 - + + + - - - - - - - - 
10 - - - - - - - - - - - - 
11 - - - - - - - - - - - - 
12 - + + + - - - - - - - - 
13 - + + - - - - - - - - - 
14 - + + - - + - - - - - - 
15 - + + + - + - - - - - - 
16 - + + - - - - - - - - - 
17 - + + - - - - - - - - - 
18 - - - - - - - - - - - - 
19 - - - - - - - - - - - - 






Caryophyllenes were found in ten samples. Even though β-caryophyllene targets selectively the CB2 
receptor and has anti-inflammatory properties, it is not a phytocannabinoid but a sequiterpene [24]. 
There are two isomeric forms of caryophyllenes: α-caryophyllene (also known as humulene) and β-
caryophyllene. They are often found in combination with α-caryophyllene or their oxidation product 
carophyllene oxide in essential oils of different spices such as oregano (Origanum vulgar L.), 
cinnamon (Cinnamomum spp.) and also Cannabis sativa [25-27]. Nerolidol was found in five samples 
and is a naturally occurring sesquiterpene alcohol. In nature, it can be found in various plants with a 
floral odour [28]. It is an additive in cosmetic and non-cosmetic products and as a flavouring agent 
[29]. Nerolidol has pharmacological and biological activities such as anti-microbial [30], anti-parasitic 
[31], anti-biofilm [32], anti-oxidant [33], anti-nociceptive [34], anti-inflammatory [34], anti-ulcer [35], 
skin penetration enhancing [36], and anti-cancer properties [29]. Nerolidol can be isolated from natural 
sources and via a chemical reaction were linalool is the starting reactant [29]. Interestingly, the 
ingredient lists of sample 5, 6 and 8 stated linalool as an ingredient. However, we could only identify 
nerolidol.  
The six identified flavours were found in sample 4 (Figure 6), which was labelled with strawberry 
flavour and had the strongest odour out of all tested e-liquids. However, sample 4 did not contain any 
of the other additives.  
 
Figure 6: a) GC-MS (EI mode): Total ion chromatogram of sample 4. b) Heightened chromatogram 
from 8 to 20 minutes, peaks labelled with the identified compounds. The six identified flavours were 
eluting between 8 and 13 minutes and the four phytocannabinoids between 16 and 19 minutes.  
Interestingly, sample 10 and 11 only contained CBD and neither any other phytocannabinoid nor 
additive. Presumably, this product was not made from plant extracts but from pure synthetic CBD, 
which is also available from internet shops. Sample 1-3 and 18-20 contained phytocannabinoids but no 
additives. Figure 7 displays the total ion chromatogram of sample 13, which contained eight different 
phytocannabinoids and two additives. The mass spectra of CBD, Δ9-THC, β-caryophyllene, 






Figure 7: a) Total ion chromatogram of sample 13. b) Heightened chromatogram from 8 to 20 
minutes labelled with the identified peaks. Eight different phytocannabinoids, eluting between 16 and 
20 minutes, and two additives, eluting at 9 minutes, could be identified.  
Quantitative analysis 
The quantification results are depicted in Table 7. The total CBD concentration could be quantified in 
all 20 samples and was in a range from 0.18 % (sample 11) to 3.35 % (sample 3).  
 
Figure 8: Calibration curves of CBD (a), THC (b), CBN (c), CBD-A (d) and THC-A (e) plotting the 
area under the curve (AUC [mAU*min]) versus the concentration [mg/mL], using weighted (1/x2) 
linear regression.  
The five analyte retention times were stable over a large number of injections and highly reproducible. 
The relative standard deviation (%RSD) of the retention time of all analytes in the quality control and 
precision samples of six runs was below 0.43 % (see Table 4). Representative chromatograms are 
depicted in Figure 8. The method showed linearity from 0.001, to 0.1 mg/mL for THC, CBD and CBN 
and from 0.01 to 0.5 mg/mL for CBD-acid and THC-acid, having correlation coefficients R2 above 
0.9986 for all analytes, using a weighted (1/x2) linear regression (see Figure 8). The LODs were 
assessed on visual examination of the chromatograms (S/N≥3) and the LLOQ were defined as the 




Table 4: Relative standard deviation (%RSD) of the retention times of all analytes in Sample A and 
the quality control samples of six runs.  
Analyte Retention time [min] n=18 standard deviation %RSD 
CBD-acid 5.68 0.02 0.410 
CBD 6.26 0.02 0.349 
CBN 7.47 0.02 0.295 
THC 8.26 0.02 0.270 
THC-acid 9.23 0.04 0.426 
 
Carry-over was determined by injecting six times pure solvent (methanol/n-hexane, 9:1, v/v) after the 
highest calibrators (THC, CBD and CBN 0.1 mg/mL and CBD-acid and THC-aid 0.5 mg/mL). No 
analyte peaks were present in the pure solvents, hence, no carry-over took place.  
For the assessment of accuracy two samples consisting of matrix (propylene glycol and glycerol) 
spiked with low (0.4 %) and high (4 %) concentrations of all analytes were measured in sextuplets. 
The accuracy was acceptable with a bias of -12.7 % to + 19 % (for the low concentrations) and -13.5 
% to –7.9% for the high concentrations, respectively. Recoveries were from 87.3 % to 119 % in the 
low concentration range and from 86.5 % to 92.1 % in the high concentration range (compare Table 
5). For the precision, additionally the two quality control samples (QC-6 and QC-11) were measured 
in sextuplets. The %RSD was between 0.22 % and 6.86 % and therefore acceptable (compare Table 
6).  
Table 5: Recovery data for e-liquid matrix (propylene glycol and glycerol) spiked with CBD, CBD-
acid, CBN, THC and THC-acid.  
Sample Analyte Spiked [%] Found [%] n=6 Recovery [%] 
A CBD 0.40 0.47 119 
CBD-acid 0.40 0.39 97.5 
CBN 0.40 0.47 116 
THC 0.40 0.47 116 
THC-acid 0.40 0.35 87.3 
B CBD 4.0 3.7 92.1 
CBD-acid 4.0 3.5 88.1 
CBN 4.0 3.5 86.5 
THC 4.0 3.5 88.4 
THC-acid 4.0 3.5 87.6 
 
Table 6: Inter-assay precision data for CBD, CBD-acid, CBN, THC and THC-acid for A (sample 
spiked with 0.4 % analyte concentration), B (sample spiked with 4 % analyte concentration), QC-6 
quality control samples spiked with CBD, CBN and THC and QC-11 quality control sample spiked 
with CBD-acid and THC-acid. .  
Sample Analyte Content [%] n=6 %RSD n=6 
A CBD 0.47 6.45 
CBD-acid 0.39 6.86 
CBN 0.47 4.51 
THC 0.47 4.82 
THC-acid 0.35 6.66 
B CBD 3.69 5.90 
CBD-acid 3.53 5.86 
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CBN 3.46 5.45 
THC 3.54 5.37 
THC-acid 3.51 5.58 
QC-6 CBD 0.11 0.32 
CBN 0.10 0.40 
THC 0.10 0.37 
QC-11 CBD-acid 0.30 0.27 
THC-acid 0.30 0.22 
 
 
Figure 9: Representative HPLC chromatograms of a) cannabinoid standards in pure solvent at 0.4 % 
analyte concentration, b) a quality control with THC, CBD and CBN (QC-6) and c) a quality control 
with CBD-acid and THC-acid (QC-11) and d) an authentic e-liquid (sample 12). Peak assignment: 1. 
CBD-acid, 2. CBD, 3. CBN, 4. THC, 5. THC-acid.  
18 
 
Table 7: Concentrations of CBD, CBD-A, CBN, THC and THC-A in the 20 tested E-liquids. For CBD and THC concentrations are given in both mg/mL and % 
(w/w).  




[%] (w/w) CBN [%] (w/w) THC [%] (w/w) THC-acid [%] (w/w) 
total THC [%] 
(w/w) 
1 not specified 1.421 - 1.420 0.00120  0.0056  0.0057 2 100 mg 0.858 85.8 0.858      3 300 mg 3.346 111.5 3.346  0.0010    4 100 mg 1.005 100.5 1.005   0.0011  0.0010 5 100 mg 0.881 88.1 0.881  0.0014 0.0011  0.0009 6 100 mg 0.817 81.7 0.817  0.0014  0.0011 0.0010 7 100 mg 0.889 88.9 0.889   0.0007  0.0006 8 100 mg 0.928 92.8 0.928  0.0009 0.0004 0.0005 0.0007 9 300 mg 3.009 100.3 3.009  0.0008 0.0069  0.0071 10 not specified 0.348 - 0.348   0.0014  0.0013 11 not specified 0.182 - 0.182   0.0011  0.0010 12 300 mg 2.787 92.9 2.778 0.0102 0.0230 0.0686 0.0427 0.1059 
13 300 mg 1.376 45.9 1.352 0.0273 0.0106 0.0100 0.0118 0.0208 
14 300 mg 2.296 76.5 2.280 0.0187 0.0242 0.0362 0.0289 0.0637 
15 1% 0.899 89.9 0.872 0.0307   0.0004 0.0003 16 1% 1.060 106.0 1.022 0.0431  0.0013  0.0012 17 1% 1.179 117.9 0.980 0.2264  0.0012  0.0011 18 1% 0.999 99.9 0.999   0.0008  0.0006 19 1% 0.816 81.6 0.816      20 1% 0.953 95.3 0.953   0.0017  0.0017 1 ratio of total determined CBD content and labeled CBD content in % 
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For all 20 tested e-liquids the total THC content was lower than 1 %, meaning no legal violations. In 
fact the total THC concentration was below 0.2 % in all samples, which is the legal cut-off in 
Germany and the European Union for THC containing hemp products [37]. CBD-acid, CBN and 
THC-acid could be quantified in seven, seven and six samples respectively. A discrepancy between 
manufacturer information on the label and the measured total CBD concentration, which we define 
here as "rel. CBD content", was observed in a range from 45.9 % (sample 13) to 117.9 % (sample 17). 
A deviation from the labelled CBD content in the range of ± 10 % (relative) was set as acceptable. 
Sample 1, 10 and 11 were from the same Swiss manufacturer and had no CBD content specification 
but were labelled "CBD rich". For sample 1, a total CBD content of 1.421 % was determined. 
However, the two flavoured e-liquids (sample 10 and 11) only contained 0.348 % and 0.182 % total 
CBD, respectively. It is questionable if such a low total CBD concentration can have any effect. 
Sample 13 and 14 from another Swiss manufacturer were labelled with a CBD content of 300 mg and 
contained lower concentrations (rel. CBD content 45.9 % and 76.5 %, respectively). These two 
samples and sample 12 (rel. CBD content 93.9 %) from the same manufacturer also contained CBD-
acid, CBN, THC and THC-acid and had the highest total THC concentrations (0.1059 %, 0.0208 % 
and 0.0637 %, sample 12, 13, 14, respectively) of all tested samples. It is surprising that products from 
the same producer have such a varying relative CBD concentration. The samples of the only non-
Swiss producer (from the UK, samples 4-9) also showed variations in the relative CBD content (rel. 
CBD content 81.7 %- 100.3 %), however also had two samples (sample 4 and 9) with the most 
accurate total CBD concentrations.  
Discussion 
Ten out of 20 analysed e-liquids had a discrepancy between the labelled CBD content and the 
determined total CBD concentration of greater than ± 10 % (relative). Of those ten e-liquids, two had a 
higher and eight a lower total CBD concentration than labelled, respectively. Furthermore, the 
determined total THC content was in all samples lower than 0.1059 %, hence below the legal 
threshold of 0.2 % in Switzerland. Peace et al. [38] analysed two commercially available e-liquids for 
their CBD content and potential additives. The two analysed samples had a relative CBD content of 
197 % and 230 % compared to the labelled content. No further cannabinoid or natural plant compound 
could be detected in the samples but 11 additives. Bonn-Miller et. al [39] investigated different CBD 
rich products (n=84) including 24 CBD rich e-liquids. They found that 12.5 % of the analysed e-
liquids were accurately labelled, 75 % had a higher CBD content than labelled and 12.5 % had a lower 
CBD content than labelled. THC was detected (up to 6.43 mg/mL) in 18 of the 84 samples tested. 
Comparable to our results, they also observed that unlabelled products contained in general a very low 
CBD concentration [39]. Pavlovic et. al [40] investigated 15 CBD-based oil preparations 
commercially available in European countries. They observed deviations from the declared CBD 
content in the range of 4.44 % to 38.14 % (w/w) for 14 of the 15 analysed samples. The unlabelled 
sample had the lowest total CBD content with 0.24 % (w/w). Rahman et al. [41] reported similar 
findings for the analysis of 69 Malaysian e-liquids for their nicotine concentration. They found that 
more than 85 % of analysed samples were inconsistent with the labelled nicotine concentration and 
argued that this is due to a lack of manufacturing guidelines. Further, Palazzolo et al. [42] reported a 
discrepancy of labelled nicotine concentration and measured concentrations in the range of 74 to 110 
% in five US e-liquids. Peace et al. [43] found in a previous study for 30 % of tested e-liquids in the 
United States a relative difference between detected concentrations and labelled nicotine 
concentrations of > plus 20 %. Furthermore, one of the analysed samples had a labelled concentration 
of < minus 40 % for  THC and < minus 50 % for CBD, respectively [43].  
According the directive 2014/40/EU of the European Parliament and of the European Council from 
April 2014, the emission levels of a nicotine cigarette must not be higher than 1 mg of nicotine per 
cigarette. It is regulated that concentrations need to be determined according to ISO 10315 [44] in the 
smoke condensate – not in the cigarette itself. Furthermore, it is stated, that nicotine-containing liquids 
are allowed to have a maximum nicotine concentration of 20 mg/mL (in the liquid). This means, that 
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for nicotine cigarettes and nicotine containing e-liquids different categories of maximum nicotine 
concentrations are considered, which makes it difficult to compare and draw conclusions from 
determined concentrations.  
In Switzerland e-liquids are categorized according to the Swiss food legislation as commodities which 
are in contact with the mucosa [45]. It is regulated that commodities of this category cannot contain 
substances with a pharmacological effect such as nicotine or disinfectant [46]. Hence, the 
supplementation of e-liquids with CBD in pharmacological effective concentrations is forbidden. 
Since it is unclear, which dose has a pharmacological effect, and due to this wording in the Food and 
Commodity Law Directory it is currently not clear which concentrations of CBD can be added to e-
liquids, hence CBD e-liquids are more or less unregulated in Switzerland. As a result, there are no 
quality specifications and requirements for manufacturers, and no regulations, how CBD-containing 
products have to be labelled. Therefore, it is hard to categorize the discrepancies observed for the 
determined and labelled CBD content. We decided to choose ± 10 % (relative) as an arbitrary 
"tolerable" level of deviation from the labelled CBD content for this study.   
In all tested e-liquids the THC concentration was below 0.2 %, which is the maximum legal THC 
concentration in the European Union. It can be stipulated that this concentration was chosen in order 
to be able to sell the e-liquids not only in Switzerland but also the European Union.  
Conclusion 
The qualitative analysis could identify in total ten phytocannabinoids including the quantified 
analytes, six natural plant compounds and five flavours. For all 20 analysed e-liquids the matrix 
consisted of 1,2-propanediol and glycerol. Our results show that all investigated e-liquids met the 
required Swiss legal regulations of a THC content lower than 1 % and had in fact contents lower than 
0.2 % (w/w), which is the maximal allowed THC concentration in the European Union. Even tough 
earlier publications reported on e-liquids containing synthetic cannabinoids, none of the analysed 
samples contained any New Psychoactive Substance (NPS). However, manufacturer information on 
the label and packaging varied drastically from the determined CBD content in a range of 45.9 % to 
117.9 %. Furthermore, variations were observed for all five investigated producers. It is unclear how 
this production error occurs because for four out of five manufacturers at least one sample contained 
the correct labelled CBD within our defined tolerance limits of ± 10% (relative). In accordance with 
previous literature the two e-liquids without specification of the CBD content contained the lowest 
total CBD concentration (0.182 and 0.348 % (w/w)).  
From our results, it can be stipulated that the e-liquids available on the Swiss market vary in quality 
concerning their CBD content and that consumers cannot rely on the manufacturer's information.  
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